MUMBAI, India, Sept. 14 -- Intellectual Property India has published a patent application (202641100106 A) filed by Saveetha Institute Of Medical And Technical Sciences on August 19, 2026, for Development Of Mikania Micrantha Extract-Integrated Chitosan/Titanium Nanocomposite Inhibiting Microbes And Its Potential Effect Against Hepg2 Cells.
Inventors include Aarthy. S; Ganesh Kumar Anbazhagan; and Deepak Nallaswamy Veeraiyan.
The application for the patent was published on September 11, 2026, under issue no. 37/2026.
Abstract: Abstract Title: Development of Mikania micrantha Extract Integrated Chitosan/Titanium Nanocomposite for Liver Cancer Therapy The present invention describes a novel plant-mediated nanocomposite comprising Mikania micrantha extract integrated within a chitosan—titanium matrix for potential liver cancer therapy. The nanocomposite is synthesized using a green, eco-friendly approach, where the plant extract acts as a natural reducing and stabilizing agent, improving biocompatibility and reducing toxicity. Physicochemical characterization is carried out using UV—Visible spectroscopy, FTIR, XRD, SEM/TEM, AFM, and zeta potential analysis. Biological evaluation includes antimicrobial, antioxidant, anti-inflammatory, and cytotoxicity studies using the HepG2 liver cancer cell line, along with reactive oxygen species (ROS) detection and Ethidium Bromide staining. The combined effect of chitosan, titanium nanomaterials, and plant-derived bioactives enhances stability, cellular uptake, and anticancer activity. This invention provides a safe, effective, and sustainable nanocomposite platform with promising potential for advanced liver cancer treatment.
Disclaimer: Curated by HT Syndication.
